Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-Related Outcomes in Hospital and Primary Care Settings: A Retrospective Cohort Study in Infants in Catalonia (Spain)
This study in Catalonia, Spain looks at the effectiveness of nirsevimab, a monoclonal antibody for RSV, in infants under 6 months old. The study shows …
Ask aRCie
Nirsevimab to Reduce Infant Morbidity From Respiratory Syncytial Virus
This article describes how nirsevimab, a long-acting monoclonal antibody, helps prevent respiratory syncytial virus (RSV) infections in infants. RSV is a common virus that can …
Nirsevimab Brings Breakthrough in the Prevention of Respiratory Syncytial Virus Infection in Infants - Importance of Design
2023
· Capital Medical University
This editorial reviews the clinical studies on nirsevimab and discusses what roles the design has played in the studies. Nirsevimab is a monoclonal antibody that …
Nirsevimab Clinical Guidance and VFC Ordering [Letter]
This letter provides clinical guidance on the use of nirsevimab (Beyfortus), a monoclonal antibody that protects infants and toddlers from respiratory syncytial virus (RSV). Information …
Nirsevimab Updates
This webinar provides updates on nirservimab. Providers will learn about the RSV season in Hawaii, the recommended immunizations for RSV prevention, and best practices for …
Obtaining Beyfortus Through the Vaccines for Children Program
This webpage explains how birthing hospitals can acquire Beyfortus through the Vaccines for Children (VFC) program. Hospitals can get Beyfortus through direct purchase or the …
Nirsevimab-A Breakthrough in Respiratory Syncytial Virus Bronchiolitis
2024
· Paris Cité University,
· McGill University
This article comments on immunization programs with nirsevimab that began in 2023 in some countries like France, with its impact being studied in recent publications. …
Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment
This article provides guidance on preventing respiratory syncytial virus (RSV) in infants. It describes two new FDA-approved options: Beyfortus, a monoclonal antibody for infants, and …
Primary Care Perspectives: Episode 154 - Nirsevimab (Beyfortus)
This podcast discusses a new preventative medicine called nirsevimab (Beyfortus), which is now available to protect infants and high-risk toddlers from respiratory syncytial virus (RSV). …
Nirsevimab for RSV Prevention in Late Preterm and Term Infants | NEJM
2022
· NEJM Group
This short video summarizes new research findings on nirsevimab and how it can prevent RSV in late preterm and term infants. The trial included 1490 …